|
| |
| | NIH Guide: PROTEASE INHIBITOR RELATED ATHEROSCLEROSIS IN HIV INFECTION |
 | | Combinations of various protease inhibitors with nucleoside and non-nucleoside reverse transcriptase inhibitors usually have synergistic effects and are used effectively in clinical practice. | | | Proposed Research The known information on the dyslipidemias and lipodystrophy associated with protease inhibitor therapy for HIV-positive patients is derived from clinical observations. | | | Four protease inhibitors are currently in use: saquinavir mesylate, ritonavir, indinavir sulfate and nelfinavir. |
|
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-00-007.html
(6761 words)
|
|
| |
| | PI3 - protease inhibitor 3, skin-derived (SKALP) |
| | Elafin and its precursor, trappin-2 or pre-elafin, are specific endogenous inhibitors of human neutrophil elastase and proteinase 3 but not of cathepsin G. | | | The increase in VEGF under hypoxic conditions was blocked by the addition of PI3 kinase inhibitors, indicating that the latter pathway is important in the hypoxic stress response. | | | PI3 kinase inhibitor, wortmannin, or a dominant-negative AKT1 expression vector treatment partially enhanced Taxol- induced apoptosis indicating that PI3 kinase-AKT pathway was involved in Taxol-resistance pathway. |
|
http://www.ihop-net.org/UniPub/iHOP/gg/91009.html
(6782 words)
|
|
| |
| | ScienceDaily: New Protease Inhibitor Held HIV At Undetectable Levels For Four Years |
| | Kaletra® is thus far the only protease inhibitor for which resistance has not been observed in patients receiving it as an initial therapy. | | | September 27, 2002 -- A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir/ritonavir (Kaletra®) suppressed HIV to undetectable levels and was well tolerated through four years of treatment in patients who had not previously received antiretroviral therapy. | | | Antiretroviral Drugs Are Not Foolproof In Preventing Sexual Transmission Of HIV, Says Pittsburgh-Rio De Janeiro Study (August 30, 2000) -- Antiretroviral therapy for HIV patients can be a double-edged sword, according to University of Pittsburgh AIDS researchers and their Brazilian colleagues. |
|
http://www.sciencedaily.com/releases/2002/09/020930075022.htm
(867 words)
|
|
| |
| | ScienceDaily: HIV Patients May Be At Risk Of Heart Problems When Taking Protease Inhibitor Drugs |
| | They investigated the hypothesis that the widely-used protease inhibitors may, in fact, be linked to the development of heart rhythm problems through the mechanism of blocking a channel. | | | After hearing of a case of heart rhythm disturbances in a patient taking protease inhibitors, the researchers looked for evidence of other patients with similar experiences. | | | They encourage physicians to be especially thorough when performing medical exams, and in taking patient histories to be alert for signs of heart rhythm disturbances. |
|
http://www.sciencedaily.com/releases/2005/02/050218161626.htm
(1148 words)
|
|
| |
| | ScienceDaily: Anthrax Toxin Inhibitor Identified; Findings Could Lead To More Effective Therapy For Deadly Agent |
| | The availability of drug inhibitors may facilitate the understanding of the effect of lethal factor on these pathways. | | | Finally, crystal structures of lethal factor protease bound to its optimal substrate and to small molecule inhibitors revealed new approaches to enable the design of better inhibitors that might prove effective for clinical use. | | | "Unlike an anti-serum, which would require that whole populations be vaccinated -- regardless of whether or not an anthrax outbreak developed -- a therapeutic combination of antibiotics and protease inhibitor drugs wouldn't have to be used except in the incidence of actual disease. |
|
http://www.sciencedaily.com/releases/2003/12/031230015204.htm
(1111 words)
|
|
| |
| | Double Protease Inhibitor Regimens Containing Vertex's HIV Protease Inhibitor, Amprenavir, Show Promise |
| | The concept behind studying two protease inhibitors together is to try to further maximize the strength of anti-HIV treatment regimens. | | | The Company is a leader in the use of structure-based drug design, an approach to drug discovery that integrates advanced biology, biophysics and chemistry. | | | The preliminary results of this study with amprenavir offer hope that this is possible." Amprenavir is currently being studied in phase III clinical trials in various combinations in various patient populations. |
|
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/2-2-98/406752&EDATE=
(985 words)
|
|
| |
| | Introduction |
| | Testimony to the great mutability of HIV is recent research that have found protease inhibitor resistant strains of HIV in patients who have never received protease inhibitor therapy before. | | | Recent research suggests that HIV gains resistance at substantial cost to protease functionality and that increased selective pressure from more protease inhibitors may lead to less virulent strains of HIV. | | | However, after the sequence of available protease inhibitors are exhausted by HIV resistance development, there are no other effective therapy options available, and the patient's CD4 |
|
http://www.stanford.edu/~siegelr/philhsu.htm
(3300 words)
|
|
| |
| | Eight Years of HIV Protease Inhibitor Therapy: |
| | The assumptions underlying this change are worth re-examining in light of improvements in protease inhibitors that have made them both simpler and more efficacious. | | | For example, data from ACTG 5095 as well as the recently discontinued ESS30009 study indicate that triple nucleoside therapy may not be sufficiently potent to be recommended as stand-alone treatment. Moreover, the resistance consequences of failing some triple nucleosides regimens can be particularly problematic. | | | Thus, there has been a resurgence of interest in the proper role of PIs in HIV treatment, and the remainder of this essay will focus on how the more recently developed drugs appear to fit into current HIV treatment approaches. |
|
http://www.hivandhepatitis.com/recent/protease/112403_essay.html
(1944 words)
|
|
| |
| | Proteases.net: protease inhibitors |
| | Protease inhibitors are important therapeutically in the management of HIV/AIDS. | | | Most naturally ocurring protease inhibitors prevent the action of serine proteases. | | | Protease inhibitors are molecules, both natural and synthetic that inhibit the activity of proteases in complex solutions such as cell lysates, blood or even within cells. |
|
http://www.proteases.net/pi.html
(437 words)
|
|
| |
| | Structural Biology |
| | Since, HIV protease recognizes various cleavage sites in the gag and gag-pol polyproteins, it is one of the examples of which one molecularsurface can recognize a variety of other seemingly non-homologous surfaces. | | | Interdependence of the conformational changes allows the protease to exhibit its wide range of substrate specificity, and also suggest the mechanism by which HIV protease achieves substrate specificity. | | | Although the crystal structure of HIV-1 protease has been solved many times in the presence of peptidomimetics and inhibitors, the complex described here (1F7A) is considered as the closest representation of an actual HIV protease-substrate complex. |
|
http://www.arches.uga.edu/~ketona/bcmb8010/Structbio.html
(2253 words)
|
|
| |
| | Biocompare News - Procyon Reports Enhanced Cross-Resistance Profile Of Its Lead HIV Protease Inhibitor, PL-100 |
| | The study described the unique resistance profile of PL-100, as assessed by in vitro susceptibility testing with a reporter-gene based phenotypic assay (PhenoSense HIV®) in comparison with six currently-marketed protease inhibitors. | | | The Company is currently completing preclinical work and expects to file an Investigational New Drug (IND/CTA) submission during the second half of 2005 in order to commence a human clinical Phase I trial shortly thereafter. | | | The Company leverages its strengths in research and clinical development, bringing products through late-stage clinical trials and then evaluating the best options for further development, such as partnerships and licensing. |
|
http://news.biocompare.com/newsstory.asp?id=66605
(789 words)
|
|
| |
| | Paradigm Therapeutics Ltd and Medivir enter alliance to discover protease inhibitor drugs |
| | "Proteases are increasingly recognised as important starting points for the development of new and effective drugs. | | | The alliance will focus on major human diseases consistent with Medivir's therapeutic interests. | | | The race to define the therapeutic utility of the thousands of uncharacterised human proteins is the new hallmark of modern drug discovery. |
|
http://www.bioportfolio.com/news/paradigm_4.htm
(588 words)
|
|
| |
| | Protease inhibitor (pharmacology) - Wikipedia, the free encyclopedia |
| | Protease inhibitors were the second class of antiretroviral drugs developed. | | | Protease inhibitors (PIs) are a class of medication used to treat or prevent infection by viruses, including HIV and Hepatitis C. | | | Protease inhibitors have been developed or are presently undergoing testing for treating various viruses: |
|
http://en.wikipedia.org/wiki/Protease_inhibitor_(pharmacology)
(348 words)
|
|
| |
| | Bugs in the News - Protease Inhibitor and HIV |
| | In many instances, such combined therapy has led to the inability to any longer detect the virus within treated patients. | | | Before I begin, if you first wish to learn a bit about HIV and AIDS, please see: HIV, AIDS and The Immune System. | | | Further, the research which led to the use of protease inhibitors for treatment of HIV infection has provided further information as to the mechanism of HIV infection, and may perhaps lead to other treatment therapies. |
|
http://people.ku.edu/~jbrown/protease.html
(1790 words)
|
|
| |
| | Pierce Biotechnology’s HALT Protease Inhibitor Cocktail - Biocompare Product Review |
| | This goal can be achieved by the time consuming process of mixing aliquots of different protease inhibitors (aprotinin, leupeptin, pepstatin, etc), some of which are toxic. | | | Pierce Biotechnology’s HALT Protease Inhibitor Cocktail - Biocompare Product Review | | | It comes in 2 forms: with EDTA and EDTA-free for instances when protein activity may be affected by the chelation of divalent cations by EDTA. |
|
http://www.biocompare.com/prorev.asp?profrevid=188
(397 words)
|
|
| |
| | Dr Garrett M. Morris |
| | HIV Protease Database maintained by Jiri Vondrasek, from Alexander Wlodawer's Macromolecular Structure Laboratory at NCI-Frederick Cancer Research and Development Center. | | | My work focuses on adding new science to AutoDock, including better search methods and parameters, better empirical free energy scoring functions, and on applying AutoDock to real-world problems in medicinal chemistry, in particular HIV-1 protease inhibitors. | | | Viruses: From Structure to Biology - explores the historical developments that led to the determination of the structure and biological functions of viruses and their macromolecular components. |
|
http://www.scripps.edu/mb/olson/people/gmm
(3985 words)
|
|
| |
| | Title of Invention: Transgenic plants expressing M. sexta protease inhibitor |
| | Specific techniques not described in detail are more fully published elsewhere, for example, see Sambrook, J. et al. | | | The Ppc1 promoter produced little if any detectable PI, using Western analysis as the criteria. | | | The antiserum was characterized by Western blot analysis of hemolymph proteins and found to be specific for the 47,000 dalton elastase inhibitor. |
|
http://www.nal.usda.gov/bic/Biotech_Patents/1995patents/05436392.html
(9627 words)
|
|
| |
| | Investigational HIV Drug Brecanavir, Positive Data For Protease Inhibitor |
| | Brecanavir is an HIV protease inhibitor in Phase 2b clinical development at GSK. | | | Investigational HIV Drug Brecanavir, Positive Data For Protease Inhibitor | | | “If approved, brecanavir may be useful in treating patients infected with strains of HIV that have become resistant to multiple protease inhibitors, and its clinical advancement underscores GSK's commitment to developing new anti-HIV drugs.” |
|
http://www.medicalnewstoday.com/medicalnews.php?newsid=35427&nfid=rssfeeds
(612 words)
|
|
| |
| | Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide |
| | Without the inhibitors, the peptide killed 18 percent, 21 percent and 40 percent of three strains and approximately 74 percent of two strains. | | | Bobek is co-author on the study, which was supported by a grant from the National Institute of Dental and Craniofacial Research. | | | One peptide in particular, called MUC7 12-mer, a piece of a larger, naturally occurring human salivary mucin molecule, has shown particular promise for treating drug-resistant fungal strains, Wei said. |
|
http://www.eurekalert.org/pub_releases/2004-03/uab-pcp030804.php
(447 words)
|
|
| |
| | Protease Inhibitor Cocktail IV by A.G. Scientific, Biochemical Manufacturer |
| | They are not intended for Human Drug, Food Additive, Clinical or Household use. | | | A specially formulated cocktail of four protease inhibitors with broad specificity for the inhibition of serine, cysteine, aspartic and metallo-proteases. | | | Protease Inhibitor Cocktail IV by A.G. Scientific, Biochemical Manufacturer |
|
http://www.agscientific.com/Item/P1513.htm
(116 words)
|
|
| |
| | An Improved Method for Subtyping Pi in Old Bloodstains |
| | Neuraminidase elution of bloodstains, together with isoelectric focusing, immunofixation, and silver staining techniques, makes possible Pi subtyping in old bloodstains. | | | Immunofixation procedures were used for detecting alpha-1 antitrypsin protease inhibitor (Pi) phenotypes in bloodstains. | | | alpha-1 antitrypsin, bloodstains, forensic science, genetic typing, human identification, immunofixation, pathology and biology, protease inhibitor, silver staining |
|
http://www.astm.org/JOURNALS/FORENSIC/PAGES/2042.htm
(208 words)
|
|
| |
| | Protease inhibitor (biology) - Wikipedia, the free encyclopedia |
| | For the drugs used in AIDS, please refer to protease inhibitor (pharmacology). | | | A1AT is indeed the protease inhibitor most often involved in disease, namely in alpha 1-antitrypsin deficiency. | | | In medicine, protease inhibitor is often used interchangeably with alpha 1-antitrypsin (A1AT, which is abbreviated P |
|
http://en.wikipedia.org/wiki/Protease_inhibitor_(biology)
(110 words)
|
|
| |
| | AEGiS-PRn: Schering-Plough Reports Novel Investigational Protease Inhibitor Shows In Vitro Antiviral Activity in ... |
| | "Hepatitis C protease inhibitors have the potential to have the same impact on HCV therapy that the HIV drugs have had," he said. | | | "Once developed, these protease inhibitors, either alone or in combination with existing therapies, may help in eradicating the hepatitis C virus in patients chronically infected with the disease. | | | More than 300,000 hepatitis C patients worldwide, including 175,000 U.S. patients, have received this combination therapy since its introduction in 2001. |
|
http://www.aegis.com/news/pr/2003/PR031048.html
(1677 words)
|
|
| |
| | New Developments in the Biology and Treatment of HIV |
| | Furthermore, many patients cannot tolerate the adverse effects associated with protease inhibitor treatment. | | | New Developments in the Biology and Treatment of HIV | | | Combination therapy, generally involving two reverse transcriptase inhibitors and a protease inhibitor, has decreased the chance of drug-resistance development compared to earlier protease inhibitor monotherapy. |
|
http://www.aegis.com/news/ads/1998/AD981895.html
(593 words)
|
|
| |
| | FDA Approves Once-Daily Combination of Abbott's Protease Inhibitor Kaletra |
| | FDA approval was based on data from a clinical study of 190 patients new to HIV therapy that compared once-daily and twice-daily Kaletra doses, both administered in combination with once-daily tenofovir and emtricitabine over a 48-week period (Dow Jones/SmartMoney.com, 5/2). | | | Pharmaceutical company Abbott Laboratories on Monday announced that the FDA has approved a once-daily formulation of its antiretroviral protease inhibitor Kaletra, which is used in combination with other drugs for initial treatment of HIV,... | | | The once-daily Kaletra -- which is a combination of the antiretroviral drugs lopinavir and ritonavir and initially was approved in a twice-daily regimen -- will be available in liquid and soft-gel formulations. |
|
http://www.medicalnewstoday.com/medicalnews.php?newsid=23867
(348 words)
|
|
| |
| | F C DENISON et al.: Uterine secretory leukocyte protease inhibitor (Journal of Endocrinology) |
| | Secretory leukocyte protease inhibitor is a potent inhibitor of neutrophil function, a mediator of mucosal immunity and an inhibitor of NFkappaB regulated inflammatory responses. | | | High levels of secretory leukocyte protease inhibitor were released by decidua (135.2±12.4 pg/mg; mean±s.e.m.) and chorio-decidua (325.1±26.4 pg/mg) with less by amnion (55.6±6.0 pg/mg) and placenta (9.2±1.9 pg/mg). | | | The increase in secretory leukocyte protease inhibitor may act to modulate pro- inflammatory paracrine interactions for the maintenance of pregnancy and limit those occurring at parturition within the uterus. |
|
http://journals.endocrinology.org/joe/161/joe1610299.htm
(325 words)
|
|
| |
| | HIV Infection: Protease and Protease Inhibitors |
| | Mutations enable HIV to avoid treatments that involve only one drug, so there is growing use of multiple-drug therapies in which both a protease inhibitor AND a reverse transcript inhibitor are combined. | | | Viral protease cuts the long chain into its individual enzyme components which then facilitate the production of new viruses. | | | Inhibitors of this viral protease can be used to fight HIV infection. |
|
http://www.cellsalive.com/hiv4.htm
(124 words)
|
|
| |
| | what's a protease inhibitor |
| | A Protease inhibitor, is used as a drug to inhibit HIV viral protease in AIDS patients. | | | Molecular Biology of an HIV infection: an interactive animation | | | But how does this help fight an HIV infection? |
|
http://www.galaxygoo.org/hiv/protease.html
(107 words)
|
|
| |
| | Protease Inhibitor 15 antibody (ab4279) datasheet |
| | Customer reviews (feedback) regarding Protease Inhibitor 15 antibody | | | cDNA cloning of a novel trypsin inhibitor with similarity to pathogenesis-related proteins, and its frequent expression in human brain cancer cells. | | | Search PubMed (MEDLINE) for references to Protease Inhibitor 15 |
|
http://www.abcam.com/?datasheet=4279
(353 words)
|
|
| |
| | Full Text - Nucleotide sequence of a genomic clone encoding a cowpea (Vigna unguiculata L.) trypsin inhibitor |
| | Gatehouse, A.M.R. and Boulter, D. Assessment of the antimetabolic effects of trypsin inhibitors from cowpea (Vigna unguiculata) and other legumes on development of the bruchid beetle Callosobruchus maculatus. | | | Many of these are products of multigene families and exhibit different specifications towards proteases (Ryan, 1990). | | | The reaction sites of these inhibitors are mutating faster than amino acids in rest of the proteins, implying their role in defense against insect pests, which may exert a strong selection pressure on these proteins to conserve the reaction sites related to plant defense (Laskowski et al. |
|
http://www.ejbiotechnology.info/content/vol4/issue1/full/4
(1963 words)
|
|
| |
| | Serine protease inhibitor Spi2 mediated apoptosis of olfactory neurons |
| | This over-expression is associated with decreased serine protease activity in the olfactory mucosa. | | | Serine protease inhibitor Spi2 mediated apoptosis of olfactory neurons | | | Hence, taken together these results document a possible novel mechanism for apoptosis induction that might occur in response to neurodegenerative insults. |
|
http://www.nature.com/cdd/journal/v9/n12/abs/4401098a.html
(300 words)
|
|
| |
| | protease inhibition - Bio-Forum |
| | there are comercially available protease inhibitors, such as benzamidine or PMSF. | | | There are other protease inhibitor mixes you can purchase also. | | | But during lysis of the cells my protein seem to be degraded. |
|
http://www.protocol-online.org/forums/index.php?showtopic=1710
(135 words)
|
|
| |
| | Inflammatory molecules released by pollen trigger allergies |
| | Next story : HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs | | | Shift in feeding behavior of mosquitoes sheds light on West Nile virus outbreaks | | | Get the most popular Biology News of the week in your Inbox! |
|
http://www.biologynews.net/archives/2005/02/21/inflammatory_molecules_released_by_pollen_trigger_allergies.html
(562 words)
|
|
| |
| | Protease inhibitor--Aprotinin activity - Bio-Forum |
| | The instruction said the activity is 10,000KIU/ml, but I want to first make a working solution 1 mg/ml, so I don't know what is its concentration. | | | I want to prepare a lysis buffer, which contains several proteinase inhibitor, among those is Aprotinin. |
|
http://www.protocol-online.org/forums/index.php?showtopic=4864
(145 words)
|
|
| |
| | Enzyme Portal for Drug Discovery |
| | P450: A superfamily of hemeproteins, may be involved in the biosynthesis of steroids, fatty acids, and bile acids, as well as the metabolism of endogenous and various exogenous substrates such as toxins and drugs. | | | International Union of Biochemistry and Molecular Biology (IUBMB) |
|
http://www.pharmtao.com/Enzyme/index.htm
(76 words)
|
|
| |
| | Protease Inhibitor Cocktails - Biocompare Buyer's Guide |
| | Protease Inhibitor Cocktail for use in Tissue Culture Media | | | ProteCEASE-100 Protease Inhibiotor Cocktail with EDTA (Each Vial makes 100ml). | | | ProteCEASE-100 Protease Inhibiotor Cocktail EDTA Free (Each Vial makes 100ml). |
|
http://www.biocompare.com/matrix/3222/Protease-Inhibitor-Cocktails.html
(197 words)
|
|
| |
| | UCB Computational Biology & Causality: Censored data & causal inference project |
| | Objectives include estimation of the effect of ART on CD4 T-cell count changes in patients with incomplete virologic suppression, estimation of the direct and indirect effects of ART, and use of history-adjusted marginal structural models to detect time-varying effect modifiers of treatment effect. | | | Study on the Consequences of the Protease Inhibitor Era (SCOPE). | | | UCB Computational Biology and Causality: Censored data and causal inference project |
|
http://www.stat.berkeley.edu/~laan/Research/Research_subpages/Causality_subpages/caus_comp_MP1.html
(116 words)
|
|
| |
| | Complete Protease Inhibitor Tablets References - Human Cells |
| | (1999) Identification of a Novel Complex between Human Kallikrein 2 and Protease Inhibitor-6 in Prostate Cancer Tissue. | | | Complete Protease Inhibitor Tablets References - Human Cells | | | Isolation of proteins from human cells using c |
|
http://www.roche-applied-science.com/ProteaseInhibitor/prod01d.htm
(389 words)
|
|
| |
| | Spink3 - serine protease inhibitor, Kazal type 3 |
| | Highly significant homology with both murine and avian type-C proteins was found within p24, p12, and the putative protease, reverse transcriptase, and endonuclease. | | | This element is homologous to the recently described binding site for the transcription factor Sp1 in the promoter sequence of the mouse p12 gene which encodes a protease inhibitor. | | | Major virion low-molecular-weight polypeptides were isolated from the Moloney strain of murine leukemia virus (type C) by agarose chromatography in 6M guanidine hydrochloride and were shown to have molecular weights of 15,000 (p15), 12,000 (p12), and 10,000 (p10) by their elution volumes and by their relative mobilities in sodium dodecyl sulfate-polyacrylamide gels. |
|
http://www.ihop-net.org/UniPub/iHOP/gg/124827.html
(5629 words)
|
|
| |
| | Links - ePitope Informatics - epitope prediction and protein analysis |
| | Computational Biology Group at UCSC (University of California, Santa Cruz). | | | Ubiquitin-proteasome system - useful info from AFFINITI Research Products. | | | Centre for Molecular and Biomolecular Informatics (CMBI) - University of Nijmegen, the Netherlands. |
|
http://www.epitope-informatics.com/Links.htm
(1840 words)
|
|
| |
| | Characterization of the protein Z-dependent protease inhibitor -- Han et al. 96 (9): 3049 -- Blood |
| | This article has been cited by other articles: | | | Protein Z-dependent protease inhibitor (ZPI) is a 72-kd member of the serpin superfamily of proteinase inhibitors that produces | | | Identification of Factor Xa Residues Critical for Interaction with Protein Z-dependent Protease Inhibitor: BOTH ACTIVE SITE AND EXOSITE INTERACTIONS ARE REQUIRED FOR INHIBITION |
|
http://www.bloodjournal.org/cgi/lookup?vol=96&fp=3049&view=abstract
(420 words)
|
|
| |
| | Molecular Biology Servers |
| | NIH - National Institutes of Health and its list of Molecular Biology Databases | | | Brookhaven National Laboratory, the Biology and Chemistry Departments | | | CATH, Protein Structure Classification at University College London,and at BNL |
|
http://web.ics.purdue.edu/~xiaoc/resources/mole.html
(289 words)
|
|
| |
| | MOLECULAR BIOLOGY OF HIV |
| | 262P - METABOLIC CONSEQUENCES OF PROTEASE INHIBITOR, NUCLEOSIDE, OR CL Cooper*, JB Angel, D Cote, I Seguin, RPG van Heeswijk, Y Khaliq, G Garber, DW Cameron | | | A Foster, R Saskin, AM Cheung, J Raboud, K Logue, G Fantas, A Assad, R Clarke, S Walmsley * | | | 260P - A PROSPECTIVE STUDY OF BODY FAT REDISTRIBUTION, LIPID AND GLUCOSE ABNORMALITIES IN HIV INFECTED PATIENTS INITIATING PROTEASE INHIBITOR BASED HAART |
|
http://www.pulsus.com/cahr2004/toc012.htm
(721 words)
|
|
| |
| | Protease and Inhibitor Web Links: Overall Lab |
| | EXOSITE, SUBSTRATE, MUTAGENESIS, PROTEIN ENGINEERING, CHEMOKINE, MASS SPECTROMETRY, ICAT, MOLECULAR BIOLOGY, CANCER, CLIP, MMP-1... | | | MMP, TIMP, MATRIX, METALLO, PROTEINASE, PROTEASE, KINETICS, ASSAYS, TISSUE INHIBITOR, PROTEOMICS, DEGRADOMICS, GELATINASE, MT-MMP, HEMOPEXIN C DOMAIN |
|
http://www.clip.ubc.ca/links.asp
(55 words)
|
|
|
